+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Overactive Bladder (OAB) Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 271 Pages
  • January 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1882057

Global Overactive Bladder (OAB) Therapeutics Market to Reach $1.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Overactive Bladder (OAB) Therapeutics estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$1.5 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2022-2030. Anticholinergics, one of the segments analyzed in the report, is projected to record a 3.1% CAGR and reach US$614.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Neurostimulation segment is readjusted to a revised 2.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $324.9 Million, While China is Forecast to Grow at 4.8% CAGR

The Overactive Bladder (OAB) Therapeutics market in the U.S. is estimated at US$324.9 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$290.7 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 2.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$190.9 Million by the year 2030.

Select Competitors (Total 34 Featured) -

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

What`s New for 2023?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Frequently Asked Questions about the Global Market for Overactive Bladder (OAB) Therapeutics

What is the estimated value of the Global Market for Overactive Bladder (OAB) Therapeutics?

The Global Market for Overactive Bladder (OAB) Therapeutics was estimated to be valued at $1.2 Billion in 2022.

What is the growth rate of the Global Market for Overactive Bladder (OAB) Therapeutics?

The growth rate of the Global Market for Overactive Bladder (OAB) Therapeutics is 2.8%, with an estimated value of $1.5 Billion by 2030.

What is the forecasted size of the Global Market for Overactive Bladder (OAB) Therapeutics?

The Global Market for Overactive Bladder (OAB) Therapeutics is estimated to be worth $1.5 Billion by 2030.

Who are the key companies in the Global Market for Overactive Bladder (OAB) Therapeutics?

Key companies in the Global Market for Overactive Bladder (OAB) Therapeutics include Allergan PLC, Astellas Pharma, Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Recordati SpA and Speciality European Pharma Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Overactive Bladder (OAB) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Neurostimulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Botox by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Mirabegron by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 16: World Overactive Bladder (OAB) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 18: USA Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 19: USA 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: Canada Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 22: Canada 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
JAPAN
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 23: Japan Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: Japan Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 25: Japan 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
CHINA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 26: China Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: China Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 28: China 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
EUROPE
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 29: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 31: Europe 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
  • Table 32: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 34: Europe 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
FRANCE
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 35: France Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: France Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 37: France 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
GERMANY
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 38: Germany Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: Germany Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 40: Germany 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
ITALY
  • Table 41: Italy Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 42: Italy Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 43: Italy 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
UNITED KINGDOM
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 44: UK Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: UK Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 46: UK 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
SPAIN
  • Table 47: Spain Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 48: Spain Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 49: Spain 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
RUSSIA
  • Table 50: Russia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: Russia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 52: Russia 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 55: Rest of Europe 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
ASIA-PACIFIC
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 58: Asia-Pacific 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 61: Asia-Pacific 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
AUSTRALIA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.